ClinVar Miner

Submissions for variant NM_000136.3(FANCC):c.487_490del (p.Glu163fs)

dbSNP: rs730881708
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000160466 SCV000211031 likely pathogenic not provided 2022-12-02 criteria provided, single submitter clinical testing Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 29922827, 30322717, 32546565, 34308366, 26681312)
Invitae RCV000528984 SCV000626250 pathogenic Fanconi anemia 2024-01-09 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Glu163Ilefs*30) in the FANCC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCC are known to be pathogenic (PMID: 17924555). This variant is present in population databases (rs730881708, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with ovarian cancer (PMID: 26681312). ClinVar contains an entry for this variant (Variation ID: 182465). For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000410607 SCV000695433 likely pathogenic Fanconi anemia complementation group C 2022-09-06 criteria provided, single submitter clinical testing Variant summary: FANCC c.487_490delGAGA (p.Glu163IlefsX30) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 2.4e-05 in 251214 control chromosomes. c.487_490delGAGA has been reported in the literature in an individual affected with ovarian cancer (example, Susswein_2015). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Baylor Genetics RCV000410607 SCV001163626 pathogenic Fanconi anemia complementation group C criteria provided, single submitter clinical testing
Ambry Genetics RCV001023180 SCV001185015 pathogenic Hereditary cancer-predisposing syndrome 2022-05-03 criteria provided, single submitter clinical testing The c.487_490delGAGA variant, located in coding exon 5 of the FANCC gene, results from a deletion of 4 nucleotides at nucleotide positions 487 to 490, causing a translational frameshift with a predicted alternate stop codon (p.E163Ifs*30). This alteration was identified in 1/10030 consecutive patients referred for evaluation by an NGS hereditary cancer panel; this patient had ovarian cancer and RAD51C c.404+2C>T variant (Susswein LR et al. Genet. Med. 2016 08;18:823-32). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Department of Pediatrics, Memorial Sloan Kettering Cancer Center RCV000410607 SCV001478122 pathogenic Fanconi anemia complementation group C 2020-12-15 criteria provided, single submitter research
Genetic Services Laboratory, University of Chicago RCV000160466 SCV002067533 likely pathogenic not provided 2020-09-08 criteria provided, single submitter clinical testing DNA sequence analysis of the FANCC gene demonstrated a 4 base pair deletion in exon 6, c.487_490del. This deletion results in an amino acid frameshift with a premature stop codon 29 amino acids downstream of the change, p.Glu163Ilefs*30. The p.Glu163Ilefs*30 change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated FANCC protein with potentially abnormal function. This sequence change has been described in the gnomAD database in six individuals with an overall population frequency of 0.002% (dbSNP rs950623649). The p.Glu163Ilefs*30 change has previously been observed in the heterozygous state in one individual with ovarian cancer (PMID: 26681312). Loss of function variants are known to be pathogenic in the FANCC gene. These collective evidences suggest this sequence change is a likely pathogenic sequence change.
Sema4, Sema4 RCV000528984 SCV002535105 likely pathogenic Fanconi anemia 2021-08-11 criteria provided, single submitter curation
Fulgent Genetics, Fulgent Genetics RCV000410607 SCV002796732 pathogenic Fanconi anemia complementation group C 2021-10-28 criteria provided, single submitter clinical testing
Counsyl RCV000410607 SCV000486096 likely pathogenic Fanconi anemia complementation group C 2017-12-28 no assertion criteria provided clinical testing
Leiden Open Variation Database RCV000410607 SCV001365297 pathogenic Fanconi anemia complementation group C 2020-02-28 no assertion criteria provided curation Curator: Arleen D. Auerbach. Submitter to LOVD: Arleen D. Auerbach.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.